Communiqués IRLAB Therapeutics AB

Actions

IRLAB A

SE0012675361

Produits pharmaceutiques

PEA

Temps Différé Nasdaq Stockholm Autres places de cotation 15:07:07 13/07/2026			Varia. 5j.	Varia. 1 janv.
1,382 ^SEK	-1,14 %		+5,50 %	-29,85 %

08/07	Irlab : James Gamgort, membre du conseil d'administration, acquiert pour près de 0,3 million de couronnes d'actions	FW
30/06	IRLAB Therapeutics AB (publ) approuve l'élection de Janne Backman au poste de vice-président du conseil d'administration	CI

Communiqués

10/07	IRLAB Therapeutics : rights issue is registered – conversion of BTA into shares	PU
30/06	Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB	AQ
16/06	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies	AQ
16/06	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies	AQ
05/06	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ
05/06	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB	AQ
03/06	IRLAB Participates at Aktiedagarna in Stockholm on June 9	AQ
03/06	IRLAB participates at Aktiedagarna in Stockholm on June 9.	AQ
06/05	IRLAB Therapeutics : Financial Report (irlab q1 2026 eng final)	PU
06/05	IRLAB Therapeutics : publishes interim report for the period January – March 2026	PU
06/05	IRLAB publishes interim report for the period January - March 2026	AQ
05/05	IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing	AQ
30/04	IRLAB: Invitation to the interim report for Q1 2026 presentation and webcast	AQ
29/04	IRLAB publishes the Annual Report for 2025	AQ
17/04	Nomination Committee's proposal to the Board of Directors for IRLAB Therapeutics' Annual General Meeting 2026	AQ
17/04	Nomination Committee’s proposal to the Board of Directors for IRLAB Therapeutics’ Annual General Meeting 2026	AQ
09/04	IRLAB to present at Redeye Healthcare Day 2026	AQ
17/03	IRLAB to Present Clinical and Preclinical Data at The AD/PD(TM) 2026 - 20th International Conference on Alzheimer's & Parkinson's Diseases	AQ
17/03	IRLAB to present clinical and preclinical data at the AD/PD™ 2026 – 20th International Conference on Alzheimer’s & Parkinson’s Diseases	AQ
02/03	IRLAB participates in Life Science Day in Gothenburg on March 4, 2026	AQ
26/02	IRLAB secures milestone payment for first patient dosed in Phase Ib study with IRL757 in Parkinson’s Disease	AQ
25/02	IRLAB Therapeutics : Financial Report (irlab year end report 2025 jan dec eng final)	PU
25/02	IRLAB publishes full-year report for the period January – December 2025	AQ
20/02	IRLAB has received scientific advisory board confirmation on next steps for pirepemat	AQ
18/02	IRLAB: Invitation to the year-end report 2025 presentation and webcast	AQ